These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 10547605)
41. Infantile and late onset form of generalised glycogenosis type II in cattle. Howell JM; Dorling PR; Cook RD; Robinson WF; Bradley S; Gawthorne JM J Pathol; 1981 Aug; 134(4):267-77. PubMed ID: 7033492 [TBL] [Abstract][Full Text] [Related]
42. [A case report of anesthesia for a child with Pompe's disease (glycogen storage disease type II)]. Sakakibara M; Teramoto Y; Aoyama T; Takahashi T; Hara M; Maseki M; Yamaguchi S; Nakata J Masui; 2009 Feb; 58(2):219-22. PubMed ID: 19227183 [TBL] [Abstract][Full Text] [Related]
43. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Sun B; Zhang H; Franco LM; Young SP; Schneider A; Bird A; Amalfitano A; Chen YT; Koeberl DD Mol Ther; 2005 Jan; 11(1):57-65. PubMed ID: 15585406 [TBL] [Abstract][Full Text] [Related]
44. Regional anesthetic techniques are an alternative to general anesthesia for infants with Pompe's disease. Walker RW; Briggs G; Bruce J; Fletcher J; Wraith ED Paediatr Anaesth; 2007 Jul; 17(7):697-702. PubMed ID: 17564654 [TBL] [Abstract][Full Text] [Related]
46. The pathology of type II skeletal muscle glycogenosis. A light and electron-microscopic study. Hudgson P; Fulthorpe JJ J Pathol; 1975 Jul; 116(3):139-47. PubMed ID: 172619 [TBL] [Abstract][Full Text] [Related]
47. Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hermans MM; van Leenen D; Kroos MA; Beesley CE; Van Der Ploeg AT; Sakuraba H; Wevers R; Kleijer W; Michelakakis H; Kirk EP; Fletcher J; Bosshard N; Basel-Vanagaite L; Besley G; Reuser AJ Hum Mutat; 2004 Jan; 23(1):47-56. PubMed ID: 14695532 [TBL] [Abstract][Full Text] [Related]
48. Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Bijvoet AG; Van Hirtum H; Kroos MA; Van de Kamp EH; Schoneveld O; Visser P; Brakenhoff JP; Weggeman M; van Corven EJ; Van der Ploeg AT; Reuser AJ Hum Mol Genet; 1999 Nov; 8(12):2145-53. PubMed ID: 10545593 [TBL] [Abstract][Full Text] [Related]
49. Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease. Umapathysivam K; Hopwood JJ; Meikle PJ Clin Chim Acta; 2005 Nov; 361(1-2):191-8. PubMed ID: 15993875 [TBL] [Abstract][Full Text] [Related]
50. Biopsy-proven alpha-glucosidase deficiency with normal lymphocyte enzyme activity. Whitaker CH; Felice KJ; Natowicz M Muscle Nerve; 2004 Mar; 29(3):440-2. PubMed ID: 14981745 [TBL] [Abstract][Full Text] [Related]
51. Late onset Tay-Sachs disease in mice with targeted disruption of the Hexa gene: behavioral changes and pathology of the central nervous system. Miklyaeva EI; Dong W; Bureau A; Fattahie R; Xu Y; Su M; Fick GH; Huang JQ; Igdoura S; Hanai N; Gravel RA Brain Res; 2004 Mar; 1001(1-2):37-50. PubMed ID: 14972652 [TBL] [Abstract][Full Text] [Related]
52. Beta-mannosidosis mice: a model for the human lysosomal storage disease. Zhu M; Lovell KL; Patterson JS; Saunders TL; Hughes ED; Friderici KH Hum Mol Genet; 2006 Feb; 15(3):493-500. PubMed ID: 16377659 [TBL] [Abstract][Full Text] [Related]